U-NEURON’s ED Drug UA002 Validates Phase 1 Safety Profile
U-NEURON (6973), a biotech companylistedon Taiwan’s Emerging Stock Market, announced on the 3rd that Phase 1 clinical trial enrollment for its novel therapeutic UA002, targeting male erectile dysfunction (ED), has been completed, with Phase 2 trials set to commence.
According to U-NEURON’s public filing, UA002 is an allogeneic amniotic fluid stem cell candidate designed to leverage stem cell repair and regenerative capabilities to treat ED patients unresponsive to oral medications. The primary objective of this Phase 1 trial was to evaluate the safety and tolerability of intracavernosal UA002 injections in non-responders to oral ED drugs, enrolling a total of 10 subjects.
U-NEURON noted that during the observation period, evaluation using the International Index of Erectile Function (IIEF-EF) questionnaire—the standard efficacy endpoint used in U.S. FDA approvals of ED drugs—revealed an improvement trend in up to 70% of patients. Among responders, over 50% achieved a Minimal Clinically Important Difference (MCID). The company explained that ED patients non-responsive to current oral therapies primarily suffer from neural damage (such as complications arising from radical prostatectomy in prostate cancer patients) or complex neurovascular injuries (such as diabetes-associated ED). Preclinical animal studies demonstrated that UA002 operates via a dual mechanism, capable of simultaneously repairing both neural and vascular tissues.
According to a market research report by Precedence Research, the global ED therapeutics market was valued at $3.19 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 8.69%, reaching $6.74 billion by 2034. While oral medications currently dominate the ED market, existing drugs present several drawbacks, including various side effects and contraindications for patients taking antihypertensive medications. Furthermore, as brand-name drugs face patent expirations and intense competition from generic PDE-5 inhibitors, strong market demand remains for innovative therapies.
Source: https://www.ctee.com.tw/news/20240104700226-439901
Source:2025.04.03 Economic Daily News / Reporter Po-Hong Hsieh
2025.04.03 Economic Daily Xie Baihong